Neurocrine Biosciences (NBIX) R&D In Process (2019 - 2025)
Neurocrine Biosciences (NBIX) has disclosed R&D In Process for 6 consecutive years, with $17.0 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, R&D In Process rose 466.67% year-over-year to $17.0 million, compared with a TTM value of $17.4 million through Dec 2025, up 39.2%, and an annual FY2025 reading of $17.4 million, up 39.2% over the prior year.
- R&D In Process was $17.0 million for Q4 2025 at Neurocrine Biosciences, up from $300000.0 in the prior quarter.
- Across five years, R&D In Process topped out at $143.9 million in Q1 2023 and bottomed at $100000.0 in Q1 2025.
- Average R&D In Process over 4 years is $19.9 million, with a median of $3.0 million recorded in 2024.
- Peak annual rise in R&D In Process hit 466.67% in 2025, while the deepest fall reached 98.33% in 2025.
- Year by year, R&D In Process stood at $5.0 million in 2021, then skyrocketed by 2778.0% to $143.9 million in 2023, then tumbled by 97.92% to $3.0 million in 2024, then skyrocketed by 466.67% to $17.0 million in 2025.
- Business Quant data shows R&D In Process for NBIX at $17.0 million in Q4 2025, $300000.0 in Q3 2025, and $100000.0 in Q1 2025.